Roche hands back rights to NewLink’s immunotherapy
Roche’s Genentech is handing back rights to NewLink Genetic’s investigational immunotherapy navoximod, pushing the latter’s stock down more than 30 percent.
Read More
Tag: GDC-0919
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
